Kopran Ltd
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.
The export percentage is about 65% of the total sales.
- Market Cap ₹ 1,232 Cr.
- Current Price ₹ 256
- High / Low ₹ 286 / 96.0
- Stock P/E 39.0
- Book Value ₹ 91.6
- Dividend Yield 1.16 %
- ROCE 8.30 %
- ROE 6.29 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 32.6%
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
199 | 250 | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 578 | |
178 | 217 | 260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 523 | |
Operating Profit | 21 | 34 | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 55 |
OPM % | 11% | 13% | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 10% |
6 | 2 | 2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 7 | |
Interest | 10 | 12 | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 8 |
Depreciation | 12 | 12 | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 12 |
Profit before tax | 5 | 11 | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 42 |
Tax % | 0% | 0% | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | |
5 | 11 | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 32 | |
EPS in Rs | 1.37 | 2.85 | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 6.54 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 12% |
3 Years: | 15% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 6% |
3 Years: | 8% |
TTM: | -37% |
Stock Price CAGR | |
---|---|
10 Years: | 28% |
5 Years: | 47% |
3 Years: | 24% |
1 Year: | 60% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 15% |
3 Years: | 15% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 39 | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 |
Reserves | 38 | 50 | 67 | 35 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 393 |
Preference Capital | 9 | 9 | 9 | 9 | 9 | 0 | 9 | 6 | 0 | 0 | 0 | 0 | |
103 | 103 | 129 | 77 | 71 | 95 | 80 | 91 | 88 | 66 | 75 | 75 | 93 | |
70 | 72 | 64 | 122 | 93 | 78 | 90 | 91 | 92 | 128 | 110 | 135 | 144 | |
Total Liabilities | 250 | 263 | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 678 |
114 | 109 | 105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 193 | |
CWIP | 19 | 20 | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 63 |
Investments | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
116 | 134 | 174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 422 | |
Total Assets | 250 | 263 | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 678 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 15 | 3 | 46 | 29 | 16 | 26 | 25 | 31 | 60 | -33 | 34 | |
-10 | -9 | -9 | -10 | -9 | -18 | -11 | -25 | -13 | -25 | -84 | -13 | |
-19 | -12 | 7 | -37 | -19 | 2 | -15 | -1 | -18 | -35 | 123 | -20 | |
Net Cash Flow | 6 | -7 | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 5 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 72 | 75 | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 |
Inventory Days | 101 | 87 | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 |
Days Payable | 120 | 111 | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 |
Cash Conversion Cycle | 52 | 50 | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 |
Working Capital Days | 59 | 74 | 108 | 67 | 80 | 109 | 121 | 117 | 126 | 113 | 200 | 177 |
ROCE % | 8% | 12% | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1 Dec
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
23 Nov - Transcript of Investor Conference call held on 22.11.2023
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 21 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Nov - Investors Conference Call to be held on Wednesday, November 22, 2023 at 4:00 PM IST
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17 Nov
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
API Vertical (57%) [1]
Development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. One of the leaders in Atenolol & one of the major players in Sterile Carbapenems. Their main products are Sterile Carbapenems (36%), Anti-Hypertensive (17%), and Macrolides (~16%). API vertical is operated by WOS Kopran Research Laboratories. [2] [3]